Open AccessThe safety of multiple oral immunotherapy in phase one studies at a single center
Author(s) -
Dominguez TLR,
Mehrotra A,
Wilson S,
Winterroth L,
Blakemore A,
Sampson K,
Nadeau K
Publication year - 2013
Publication title -
clinical and translational allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.979
H-Index - 37
ISSN - 2045-7022
DOI - 10.1186/2045-7022-3-s3-o25
Subject(s) - medicine , oral immunotherapy , single center , center (category theory) , immunotherapy , medical physics , family medicine , cancer , chemistry , crystallography
Background There are over 15 million people with food allergies, 38% of which suffer from more than 1 food allergy. With increasing interest in oral immunotherapy (OIT) as a potential treatment, the safety of ingesting known allergens is a major concern. Little to no data are available for OIT with multiple simultaneous allergens. Also, the effect of omalizumab as adjunctive therapy in rush multi OIT had not been investigated.